Reviewer's report

Title: Impact of Efalizumab on Patient-Reported Outcomes in High-Need Psoriasis Patients: Results of the International, Randomized, Placebo-Controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) Trial [IMP24011]

Version: 1 Date: 6 October 2005

Reviewer: jennifer cather

Reviewer's report:

General
Try to shorten the paper - the data are similar to that of the large clinical trials.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept after minor essential revisions

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I am a consultant and have don clinical trials with Efalizumab